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Regulation of cyclin D1 expression and cell cycle progression teins called cyclins. Cyclins act in concert with the cyclin-
by mitogen-activated protein kinase cascade. Mitogen-acti- dependent kinases (CDKs) to phosphorylate key sub-
vated protein kinases (MAPKs) have been shown to play an strates that facilitate the passage of the cell through eachimportant role in transducing extracellular signals into cellular
phase of the cell cycle, for example, retinoblastoma tu-responses. The classic MAPK pathway is commonly activated
mor suppressor protein [1, 2].by growth factors and has been shown to play a crucial role
in cell proliferation. Transforming growth factor-b (TGF-b)– When cells enter the cell cycle from quiescence (G0),
activating kinase-1 (TAK1) is a novel MAPK kinase kinase d-type cyclins and cyclin E are synthesized sequentially
that is reported to stimulate the MKK6-p38K pathway. To during the G1 interval, both being rate limiting forelucidate the functional roles of the TAK1 pathway, we trans-
S-phase entry. Genes encoding D-type cyclins (D1, D2,fected its constitutive active form (TAKdN) and negative form
and D3) are progressively induced as a part of the re-(TAKK63W) to LLC-PK1 cells. TAKdN stimulated MKK6
phosphorylation and p38K activity and inhibited the percent- sponse to mitogenic stimulation. The mechanisms of
ages of the S and G2/M phases. TAKK63W, the constitutive D-type cyclin expression are poorly understood.
negative form, reduced TGF-b–stimulated MKK6 phosphory-
Mitogen-activated protein kinases (MAPKs) havelation and p38K activity and increased the percentages of the
been reported to play an important role in transducingS and G2/M phases. The cyclin D1 protein level is reduced by
the TAK1 pathway. We also examined the effects of the TAK1 extracellular signals into cellular responses. The classic
pathway on cyclin D1 promoter-luciferase assay. The overex- MAPK pathway (simply called MAPK in this article;
pression of TAKdN or p38K inhibited cyclin D1 promoter also known as ERK) is commonly activated by growthactivity. In contrast, overexpression of the active form of
factors and has been shown to play a crucial role inMKK1, the classic MAPK-activator, MKK1 increased cyclin
cell proliferation and early development. We previouslyD1 promoter activity and protein level, as well as the percent-
ages of S and G2/M phases. reported that MAPK cascades are expressed every neph-
ron segment and that many hormones and cytokines
activate MAPK cascades and regulate cell function [3–5].
Our findings suggested that the growth-inhibitory ef- Transforming growth factor-b (TGF-b) plays an im-
fects of TGF-b are at least partially mediated by the portant role in the pathophysiology of renal diseases,
TAK1-MKK6-p38K pathway in LLC-PK1 cells. The including glomerulosclerosis, tubular cell inflammation,
TAK1-MKK6-p38K pathway negatively regulates cyclin fibrosis, and hypertrophy. Recently, Yamaguchi et al
D1 expression and cell cycle progression, whereas the identified a novel MAPKKK termed TAK1 (TGF-b–
MKK1-p42/44 MAPK pathway up-regulates cyclin D1 activating kinase) [6]. TAK1 is reported to participate
expression and cell cycle progression. in the signal transduction of TGF-b and the phosphoryla-
Recently, a number of major advances in molecular tion of the p38K and/or SAPK(JNK) pathway [7]. TGF-b
biology have led to the identification of several critical exerts antiproliferative effects in a number of cells that
genetic and enzymatic pathways that control cell prolif- are at least partially mediated by inhibition of pRb phos-
eration. We now know that the progression of the cell phorylation and blockage of the cell cycle at the G1/S
cycle is controlled in part by a series of protein kinases, phase [8, 9]. The participation of the TAK1-MKK3/6-
the activities of which are regulated by a group of pro- p38 kinase pathway in TGF-b–induced antiproliferative
effects has not been evaluated.
It is of interest to study how these signal transductionKey words: MAPK, extracellular signaling, TAK1, p38 kinase, cyclin
kinase inhibitor, renal tubular cells. pathways regulate cell cycle and proliferation in renal
tubular cells. We have investigated the functional roles 1999 by the International Society of Nephrology
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of the TAK1-MKK3/6-p38K pathway and classic MAPK However, the mechanisms of this stimulatory action re-
main unclear. In cultured cell lines, mitogenic stimula-cascades in cell cycle progression, especially in the tran-
scriptional regulation of the cyclin D1 gene (abstract; tion by growth factors correlates with stimulation of
p42/44 MAP kinase. Constitutive negative mutants ofTerada et al, J Am Soc Nephrol 8:448, 1997). Further
information in this field may provide new insights for Ras or Raf-1, the upstream components of MEK in the
ERK pathway, were shown to inhibit cell cycle progres-understanding renal pathophysiology that may lead to
novel therapeutic approaches. sion induced by growth factors, whereas constitutive ac-
tive forms of Raf-1 have been reported to promote cell
proliferation. Furthermore, the constitutive negativeCELL CYCLE REGULATION BY p42/44 MAPK
form of MEK inhibits proliferation of NIH3T3 cells,CASCADE AND TAK-MKK6-p38K CASCADE IN
whereas the constitutive active form of MEK has beenRENAL TUBULAR CELLS
shown to induce cellular transformation or proliferation
Cellular proliferation accompanies a wide variety of [12]. Although these studies suggest that the ERK cas-
renal diseases. This is especially true for proliferative cade plays a pivotal role in the control of cell cycle
forms of glomerulonephritis and renal tubular degenera- progression, further studies are necessary to determine
tion after acute renal failure. The following cytokines the mechanisms of stimulatory effects of ERK pathway
have been implicated in the pathogenesis of proliferative in the cell cycle regulation.
glomerulonephritis and acute renal failure, and are Thus, we examined the role of the MKK1-ERK path-
thought to account for cellular proliferation and regener- way in the regulation of cyclin D1 promoter activity and
ation: platelet-derived growth factor (PDGF), TGF-b, protein expression. Cyclin D1 promoter activity in-
interleukin (IL)-1, IL-6, epithelial growth factor (EGF), creased significantly when a dominant active form of
insulin-like growth factor-I (IFG-I), and tumor necrosis MKK1 (S222E) was transfected, and it was inhibited by
factor (TNF) [10]. A common feature of these stimuli is PD98059 (MKK1 inhibitor). Conversely, transfection of
their ability to activate MAP kinase families in vitro in dominant-negative MKK1 (S222A) produced a marked
a variety of cell lines. Recently, Bokemeyer et al reported inhibition of cyclin D1 promoter activity. We next exam-
that the activation of p42/44 MAPK plays a crucial role ined the regulation of cyclin D1 protein expression when
in the pathogenesis of Thy1.1 glomerulonephritis [11]. these MKK1 mutants were overexpressed. The protein
The classical p42/44 MAPK is known to be an intracellu-
level of cyclin D1 was increased in the cell transfected
lar checkpoint for cellular mitogenesis, and activation
with the active form of MKK1. In contrast, the proteinof this kinase might be a crucial mediator of cellular
level of cyclin D1 was reduced in cells expressing MKK1proliferation in renal diseases mediated by the extracel-
(S222A).lular stimuli listed earlier in this article. We observed
that the constitutive active form of MKK1, the activator
of classic MAP kinase, increased thymidine uptake to DOWN-REGULATION OF CYCLIN D1
250% in the absence of FCS. Wild-type MKK1 slightly EXPRESSION BY THE TAK1-MKK6-
increased [3H]-thymidine uptake, and constitutive nega- p38 PATHWAY
tive MKK1 did not increase [3H]-thymidine uptake in We next examined the mechanisms of the TAK1 path-
LLC-PK1 cells. way on cell cycle progression of renal tubular cells.
On the other hand, TGF-b has been reported to be Transfection of constitutive active form (TAKdN) inhib-
one of the most important modulators in the pathogene- ited the [3H]-thymidine and the percentages of S and
sis of glomerulonephritis or renal tubular fibrosis. We G2/M phases even in the absence of TGF-b.
examined the effects of the TAK1 pathway on cell pro- LLC-PK1 cells transfected with the cyclin D1-lucifer-liferation of LLC-PK1 cells by thymidine uptake and ase reporter gene responded to TGF-b with a significant
FACS scan. Transfection of the constitutive active form
decrease in reporter gene activity [13]. Because the most
(TAKdN) inhibited the [3H]-thymidine and the percent-
significant inhibition of cyclin D1 promoter activity wasages of S and G2/M phases even in the absence of TGF-b.
observed in cells transfected with TAKdN, MKK6 (Glu;This inhibition by TAKdN was recovered by the p38K-
active form) [14], and p38K (TGY; active form), thisspecific inhibitor SB203580. Transfection of constitutive
down-regulation of cyclin D1 reporter activity in TGF-negative TAKK63W plasmid partially recovered the
b–treated cells was likely to have resulted from an activa-growth-inhibitory effects of TGF-b.
tion of the TAK1-MKK6-p38K pathway. Conversely,
cotransfection of MKK6 (Ala; negative form) or p38K
UP-REGULATION OF CYCLIN D1 EXPRESSION (AGF; negative form) ameliorated the inhibitory effects
BY THE MKK1-p44/p42 MAPK PATHWAY of TAKdN on cyclin D1 promoter activity. SB203580
also abolished the inhibitory effects of TAKdN on cyclinMany articles have demonstrated the promotive ef-
fects of the p42/44 MAPK pathway on cell proliferation. D1-luciferase expression. These data suggested that the
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Fig. 1. Possible interactions between mito-
gen activated protein kinases (MAPK) path-
ways and the cell cycle.
inhibitory effect of TAK1 on cyclin D1 promoter activity of these kinases really regulates cell cycle progression.
Thus, the questions remained as to whether the MKK3/is transduced by the MKK6-p38 kinase pathway (Fig. 1).
Cyclin D1 protein levels were also decreased in cells 6-p38 kinase pathway is involved in the antiproliferative
effects of TGF-b and whether or not the inhibitory ef-transfected with the constitutive active TAKdN con-
struct. fects of TGF-b in cell cycle progression are mediated by
inhibiting the transcriptional regulation of cyclin D1.Thus, the TAK1-MKK6-p38 kinase pathway nega-
tively regulated cyclin D1 expression transcriptionally. Our current studies demonstrate that the TGF-b–TAK1
pathway inhibited cyclin D1 promoter activity and cell
cycle progression via the MKK3/6-p38 kinase pathway.
DISCUSSION In contrast, growth factors stimulate the classic MAPK
Cellular proliferation accompanies a wide variety of pathway, increase cyclin D1 promoter activity, and then
renal diseases such as glomerulonephritis and acute renal stimulate cell cycle progression. Thus, the contour bal-
failure. In these pathological states, many growth factors ance of p42/44 MAPK and p38K may play a crucial role
modulate proliferative change. On the other hand, TGF-b in the pathogenesis of glomerulonephritis and tubular
has been also reported to play a crucial role in the pro- regeneration. An understanding of the signal transduc-
gression of glomerulonephritis and interstitial fibrosis tion system and the cell cycle regulation is essential for
[15, 16]. Transgenic mice overexpressing constitutively the rational design of novel pharmacotherapeutic ap-
active TGF-b revealed that TGF-b overexpression was proaches to acute renal failure and proliferative glomer-
associated with tubular flattened atorophic tubular epi- ulonephritis.
thelial cells and tubulointerstitial fibrosis [17]. Recently,
Jiang et al reported that p38Kd is activated in Thy1.1 ACKNOWLEDGMENTS
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